This Article Full Text Full Text (PDF) All Versions of this Article: 146/7/3037    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miyazaki, T. Articles by Mori, T. Search for Related Content PubMed PubMed Citation Articles by Miyazaki, T. Articles by Mori, T.

Therapeutic Effects of Tolvaptan, a Potent, Selective Nonpeptide Vasopressin V₂ Receptor Antagonist, in Rats with Acute and Chronic Severe Hyponatremia

Research Institute of Pharmacological and Therapeutical Development, Otsuka Pharmaceutical Co., Ltd., Tokushima 771-0192, Japan

Address all correspondence and requests for reprints to: Toshiki Miyazaki, Research Institute of Pharmacological and Therapeutical Development, Otsuka Pharmaceutical Co., Ltd., 463-10 Kagasuno Kawauchi-cho Tokushima 771-0192, Japan. E-mail: t_miyazaki{at}research.otsuka.co.jp.

The therapeutic efficacy of tolvaptan (OPC-41061), a potent, selective nonpeptide vasopressin V₂ receptor antagonist, on acute and chronic severe hyponatremia was assessed in rats. Experiments were designed to demonstrate the efficacy of tolvaptan reducing mortality in an acute model, and controlling the extent of serum sodium elevation without causing abnormal animal behavior suggesting neurological symptoms in a chronic model. In the acute model, rats developed rapidly progressive, severe hyponatremia by continuous sc infusion of [deamino-Cys¹, D-Arg⁸]-vasopressin (10 ng/h) and forced water-loading (additional 10% initial body weight per day). By d 6, untreated rats had a 47% mortality rate. However, rats treated with repeated oral administrations of tolvaptan (1, 3, and 10 mg/kg) produced dose-dependent aquaresis (i.e. urine volume increased and urine osmolality decreased) that resulted in a gradual increase in plasma sodium concentration. Consequently, tolvaptan treatment reduced mortality and, at higher doses, resulted in no observed deaths. In the gradual model, rats receiving a continuous sc infusion of [deamino-Cys¹, D-Arg⁸]-vasopressin (1 ng/h) combined with a liquid diet were induced to stable, severe hyponatremia (110 mEq/liter), which lead to increased organ weight and water content. Rats receiving dose titrations of tolvaptan (0.25, 0.5, 1, 2, 4, and 8 mg/kg) increased plasma sodium to healthy levels without causing abnormal animal behavior suggesting neurological symptoms or death, improved hyponatremia-driven increases in wet weight and water content in the organs. Thus, in animal models, analogous to the hyponatremia forms seen in humans, tolvaptan presents exciting therapeutic implications in the management of patients with severe hyponatremia.

This article has been cited by other articles:

				A. Soupart, B. Schroeder, and G. Decaux Treatment of hyponatraemia by urea decreases risks of brain complications in rats. Brain osmolyte contents analysis Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1856 - 1863. [Abstract] [Full Text] [PDF]

				W. G. Purschke, D. Eulberg, K. Buchner, S. Vonhoff, and S. Klussmann An L-RNA-based aquaretic agent that inhibits vasopressin in vivo PNAS, March 28, 2006; 103(13): 5173 - 5178. [Abstract] [Full Text] [PDF]